|Bid||3.11 x 4000|
|Ask||3.20 x 2900|
|Day's Range||3.1200 - 3.2200|
|52 Week Range||1.9900 - 3.9300|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.45|
While small-cap stocks, such as Antares Pharma, Inc. (NASDAQ:ATRS) with its market cap of US$484m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...
If you want to know who really controls Antares Pharma, Inc. (NASDAQ:ATRS), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in Read More...
Antares Pharma, Inc. (ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors. Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of Cerecor Inc. (CERC), a biopharmaceutical company focused on neurological and pediatric disorders. He is also Chairman of the Board at BioDelivery Sciences (BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine.
The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019.
Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Antares Pharma, Inc. (ATRS) today announced the availability of XYOSTED™ (testosterone enanthate) injection. XYOSTED™ is the only FDA approved subcutaneous testosterone product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector. XYOSTED™ has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (see Indications and Usage below). XYOSTED™ was approved by the U.S. Food and Drug Administration (“FDA”) on September 28, 2018.
Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.
Teva Pharmaceutical Industries on Tuesday released limited doses of its generic version of EpiPen Auto-Injector. Its generic EpiPen, developed in a partnership with New Jersey-based Antares Pharma, is carrying a price tag of $300. Mylan has come under criticism by government agencies and consumers because of price increases that have driven up the cost of the branded EpiPen injector from less than $100 to more than $600 during the past decade.
Antares Pharma, Inc. (ATRS) (“Antares”) today announced that Teva Pharmaceutical Industries, Ltd.’s (“Teva”) generic EpiPen® is now commercially available in limited quantities. Teva’s generic EpiPen® was approved by the U.S. Food and Drug Administration (“FDA”) on August 16, 2018 and is indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients. The product, which utilizes the Antares Pharma VIBEX® auto injector, has been approved as therapeutically equivalent and fully substitutable to the EpiPen® at the pharmacy.
Highlights for the quarter and quarter to date include FDA approval of Xyosted, FDA approval generic epinephrine pen and a new partnership with Pfizer (PFE). Strong sales of Makena at partner AMAG (AMAG) and optimism over a 2018 start to Xyosted sales were offset by weaker than expected sales for Otrexup and Sumatriptan. Antares Pharma, Inc. posted third quarter 2018 revenues of $17.9 million, representing 19% growth compared to prior year results of $15.1 million.
Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
Woodcliff Lake, NJ, based Investment company Healthcare Value Capital, LLC buys Antares Pharma Inc, sells Novelion Therapeutics Inc during the 3-months ended 2018-09-30, according to the most recent filings ...
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Antares Pharma, Inc. have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 21, 2016 and October 12, 2017.
The Ewing, New Jersey-based company said it had a loss of 1 cent per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
Antares Pharma Inc’s (NASDAQ:ATRS): Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s loss has recently broadened since Read More...
In Q2 2018, partner Amag Pharmaceuticals (AMAG) reported revenues of $105.2 million for Makena, which is a year-over-year (or YoY) rise of 2.43%. According to Antares Pharma’s Q2 2018 conference call, this growth was driven mainly by the increased overall uptake of the product coupled with the launch of the Makena auto injector in the US market in March 2018. As per AMAG Pharmaceuticals’ estimates based on distributor dispensing data and physician market research data from its investor presentation, Makena accounted for a 51% share of the total market for preventing pre-term birth in at-risk women.